LivaNova PLC 10-Q Summary: Q1 2024
Business Context and Reporting Period
LivaNova PLC is a global medical technology company focused primarily on Cardiopulmonary and Neuromodulation products. This report covers the three months ended March 31, 2024, compared with the same period in 2023, and was filed May 3, 2024. The financial statements are unaudited, prepared under U.S. GAAP, and reported in U.S. dollars.
During the quarter, LivaNova reorganized its reporting structure from three segments to two. ACS standalone cannulae and accessories were moved into Cardiopulmonary, while other ACS operations, including LifeSPARC and Hemolung, are being wound down by the end of 2024.
Financial Performance and Key Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $294.9 million | $263.4 million | 12.0% increase |
| Gross profit | $207.4 million | $174.1 million | 19.1% increase |
| Gross margin | 70.3% | 66.1% | 4.2 percentage-point increase |
| Operating income (loss) | $16.2 million | $(2.3) million | Improved |
| Operating margin | 5.5% | (0.9)% | Improved |
| Net income (loss) | $(41.9) million | $7.4 million | Declined |
| Diluted EPS | $(0.78) | $0.14 | Declined |
| Operating cash flow | $10.0 million | $20.8 million | Declined $10.8 million |
- Cardiopulmonary revenue increased 14.8% to $155.9 million, driven by Essenz Perfusion System sales and strong worldwide consumables demand. Segment income increased 60.4% to $14.7 million.
- Neuromodulation revenue increased 10.9% to $133.9 million, with double-digit growth in the United States and Rest of World. Segment income increased 72.8% to $46.7 million.
- Cost of sales declined to 29.7% of revenue from 33.9%, reflecting product mix and the ACS wind-down. SG&A declined to 44.0% of revenue from 47.1%, and R&D declined to 15.5% from 19.0%.
- Net loss included a $25.5 million loss on extinguishment of debt, $15.9 million of interest expense, $9.1 million of foreign exchange and other expense, $9.2 million of restructuring expense, and a $6.4 million increase in the 3T Heater-Cooler litigation provision.
- Cash, cash equivalents and restricted cash totaled $615.7 million at March 31, 2024, including $309.2 million of unrestricted cash and $306.5 million of restricted cash collateralizing the SNIA litigation guarantee.
- Working capital was $712.2 million. Total debt obligations were $624.5 million, including $604.8 million of long-term debt. No borrowings were outstanding under the revolving credit facility.
Material Changes Versus the Prior Comparable Period
- Revenue increased $31.5 million, or 12.0%, with growth in both reportable segments and all geographic regions.
- Gross margin and operating income improved materially, but bottom-line results reversed to a loss primarily because of debt extinguishment costs, higher interest expense, unfavorable derivative valuation changes, and restructuring and litigation charges.
- Operating cash flow fell to $10.0 million from $20.8 million, mainly because of changes in operating assets and liabilities.
- On March 8, 2024, LivaNova issued $345.0 million of 2.50% convertible senior notes due 2029. It used part of the proceeds to repurchase $230.0 million principal amount of 2025 Notes for $270.5 million and unwound a corresponding portion of the 2025 capped calls.
- The company increased available revolving credit commitments from $125.0 million to $225.0 million, with maturity in March 2029.
- Restricted cash declined by $4.9 million from year-end, while unrestricted cash increased by $42.7 million.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing does not provide clear quantitative full-year revenue, earnings, or cash-flow guidance. Management stated that available liquidity is expected to fund operating needs, working capital, capital expenditures, acquisition earn-outs, and debt service for the twelve months following the filing.
- The 2024 Restructuring Plan is expected to generate approximately $15 million to $20 million of pre-tax charges, including $10 million to $12 million of severance and retention costs and $5 million to $8 million of other expenses. Most severance costs are expected in the first half of 2024, with substantially all related cash payments expected during 2024.
- The company detected a cybersecurity incident in November 2023. Direct costs totaled $5.4 million through March 31, 2024, including $2.8 million in Q1 2024. Additional costs are expected, and insurance coverage may not reimburse all costs.
- The company recorded a $20.0 million provision for 3T Heater-Cooler product liability matters at March 31, 2024. Approximately 65 filed and unfiled claims were known worldwide as of May 3, 2024, and actual liability could exceed the provision.
- LivaNova faces substantial SNIA environmental litigation exposure. A Court of Appeal decision ordered damages of approximately €453.6 million, but the company has not recorded a liability because a potential loss is not currently considered probable. A €270.0 million first-demand bank guarantee is supported by restricted cash collateral. Final Italian and European court decisions are not expected until at least 2025.
- The company had $8.4 million reserved for the Italian medical-device payback matter. The ultimate liability could differ, and related proceedings remain subject to legal uncertainty.
- Macroeconomic risks include foreign-exchange volatility, inflation, geopolitical instability, supply-chain constraints, labor and capacity pressures, changing interest rates, cybersecurity threats, regulatory and reimbursement changes, product liability, and intellectual property risks.
- The company was in compliance with its credit agreement financial covenants at March 31, 2024. However, debt service, potential cash settlement of the 2025 Notes, and potential conversion-related obligations under the 2029 Notes could pressure liquidity.
- The OSPREY clinical study for the aura6000 obstructive sleep apnea system achieved a positive predictive outcome, with the company stating a greater than 97.5% probability of meeting its primary endpoint and earlier-than-expected completion of enrollment.
- Revenue attributable to Iranian activities was $3.7 million and related net profit was $1.9 million for the quarter. The company believes the activities comply with applicable sanctions laws but noted that the regulatory environment is complex and evolving.
Important Facts for Investors to Verify
- Whether revenue growth and segment profitability persist after the ACS wind-down and restructuring activities are completed.
- The timing and total cash cost of the 2024 Restructuring Plan, including whether estimated charges remain within the $15 million to $20 million range.
- Future cash requirements related to the 2025 Notes, 2029 Notes, term facilities, and potential cash settlement of exchange or conversion obligations.
- The ultimate cost and settlement timing of 3T Heater-Cooler claims, SNIA litigation, the Italian medical-device payback matter, and Saluggia environmental obligations.
- The continuing financial and legal impact of the cybersecurity incident, including insurance recoveries and any data-notification consequences.
- Whether the OSPREY trial ultimately meets its primary endpoint and obtains the necessary regulatory approvals.
- The effect of derivative fair-value changes, foreign exchange movements, interest rates, and share-price volatility on reported earnings.
- The company’s ability to convert operating income improvements into sustained positive operating cash flow.